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Perchlorate is one of several monovalent
anions that have been shown to competitively
inhibit thyroidal iodide uptake (Wyngaarden
et al. 1952). At sufficiently high doses, per-
chlorate can block iodine uptake and thus
inhibit thyroid function. This characteristic of
perchlorate has been used in the treatment of
Graves disease, a condition characterized by
hyperthyroidism (Crooks and Wayne 1960;
Godley and Stanbury 1954). The specific
iodide transporter protein at which perchlo-
rate competitively inhibits iodine uptake has
been characterized (Dai et al. 1996).
The discovery of the widespread presence
of low concentrations of perchlorate in drink-
ing water in the southwestern United States
(Urbansky 2002) has led to concern regarding
the possibility that environmental perchlorate
may induce a relative iodine deficiency and
thereby decrease thyroid hormone produc-
tion. If this were to happen during pregnancy
among women with lower iodine intake,
adverse neurodevelopmental outcomes in the
fetus could result.
In response to these concerns, the U.S.
Environmental Protection Agency (EPA) has
undertaken to determine a reference dose
(RfD) for perchlorate in drinking water. In
2003, the agency asked the National Academy
of Sciences (NAS) to review the science sup-
porting potential toxicity of perchlorate. An
NAS committee recently reported their ﬁnd-
ings regarding the health implications of per-
chlorate ingestion (NAS 2005). In their report,
the committee stated:
• “Inhibition of iodide uptake by the thyroid
clearly is not an adverse effect.”
• “To cause declines in thyroid hormone pro-
duction that would have adverse health
effects, iodide uptake would most likely have
to be reduced by at least 75% for months or
longer.”
• “The committee does not agree that transient
changes in serum thyroid hormone or TSH
[thyroid-stimulating hormone] concentra-
tions are adverse health effects; they are sim-
ply biochemical changes that might precede
adverse effects.”
• “The committee concludes that the first
adverse effect in the continuum would be
hypothyroidism. Any effects that follow and
result from hypothyroidism clearly would
be adverse.”
The committee also concluded that “on
the basis of the studies of long-term treatment
of hyperthyroidism in which patients contin-
ued to be given perchlorate after their hyper-
thyroidism resolved . . . the perchlorate dose
required to cause hypothyroidism in adults
would probably be more than 0.40 mg/kg per
day,” thus establishing a no observed adverse
effect level (NOAEL) (NAS 2005).
The NAS further recommended an RfD
of 0.0007 mg/kg-day based on a no observed
effect level (NOEL) for iodine uptake inhibi-
tion provided by Greer et al. (2002) and a
10-fold uncertainty factor. They stated that
this “value is supported by other clinical
studies, occupational and environmental epi-
demiologic studies, and studies of long-term
perchlorate administration to patients with
hyperthyroidism.”
The U.S. EPA formally adopted the RfD
of 0.0007 mg/kg-day recommended by the
NAS committee. The agency deﬁnes an RfD
as “an estimate (with uncertainty spanning
perhaps an order of magnitude) of a daily oral
exposure to the human population (including
sensitive subpopulations) that is likely to be
without deleterious noncancer effects during
a lifetime” (U.S. EPA 2002). Given a body
weight and a daily drinking water consump-
tion, an RfD can be converted to an equiva-
lent concentration in drinking water.
Traditionally, an RfD has been calculated
by dividing a NOAEL by various safety fac-
tors. More recently a benchmark calculation
has been used instead of a NOAEL in the
determination of an RfD. A benchmark dose
(BMD) is a dose corresponding to a prescribed
increase in an adverse response (Budtz-
Jørgensen et al. 2001; Crump 1984, 1995,
2002a, 2002b; Gaylor and Slikker 1990;
Kodell et al. 1995; West and Kodell 1993). A
statistical lower bound on the BMD (BMDL)
replaces a NOAEL in determining an RfD
(U.S. EPA 2000a, 2000b). A BMDL has
several potential advantages over a NOAEL,
including better reflection of the power of
a study to detect effects, better use of dose
response information from a study, and less
dependence on the spacing of doses in a study.
A BMDL can be calculated from data in which
adverse responses occur at every dose, such that
no NOAEL can be deﬁned, and also from neg-
ative data in which there is no clear evidence of
a dose-related effect (Crump et al. 2000).
Although an RfD can be calculated from
either animal or human data, it is generally
agreed that use of human data is appropriate
whenever suitable human data are available.
The NAS found that in the case of perchlorate,
the animal data were not conclusive and that
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Researchthe human data are more than sufficient for
risk assessment. They based their RfD on the
NOEL for inhibition of radioactive iodine
uptake (RAIU) from Greer et al. (2002), who
studied thyroid function in volunteers given
perchlorate in drinking water for 14 consecu-
tive days. Two other studies of thyroid effects
in humans exposed occupationally to perchlo-
rate have been conducted that contain data
suitable for supporting a benchmark analysis.
Lamm et al. (1999) studied thyroid function of
long-term ammonium perchlorate workers at a
facility in Utah. Braverman et al. (2005) con-
ducted a similar study of long-term workers
from the same Utah facility. The workers typi-
cally worked three 12-hr shifts followed by
3 days off. Each of these studies evaluated vari-
ous measures of thyroid function and either
assigned perchlorate doses or collected serum
or urine samples that could be used to quantify
perchlorate exposure.
Not all of the different thyroidal end
points that were evaluated in these studies are
suitable to develop a BMDL. The various thy-
roidal measurements made included RAIU,
thyroid volume, thyroglobulin (Tg), tri-
iodothyronine (T3), total thyroxine (T4), free
T4 (FT4), free T4 index (FTI), and TSH. T3
and T4 are the active thyroid hormones, and
they can be either bound to serum proteins or
free. Increases in Tg and thyroid volume are
generally considered adaptive responses. FTI
and FT4 are comparable quantitative measure-
ments of non-protein-bound T4 in the serum.
The adverse outcome of most concern is a
delay in T4-dependent neuronal cell migration
during fetal development that occurs near the
late ﬁrst trimester and early second trimester
(Lavado-Autric et al. 2003). At this critical
early stage of pregnancy, the fetal thyroid is not
yet functional, and the only source of fetal thy-
roid hormone is T4 that crosses the placenta
from the maternal circulation. With maternal
hypothyroidism, maternal T4 decreases signiﬁ-
cantly, resulting in a corresponding decrease of
fetal thyroid hormone levels and also triggering
an increase in maternal TSH.
Recent epidemiologic studies in Europe
and the United States have concluded that
maternal hypothyroidism during pregnancy,
even when mild and considered subclinical,
and especially when occurring during early ges-
tation, may be associated with an impairment
of normal brain development and intelligence
in offspring (Haddow et al. 1999; Pop et al.
1999). Maternal FT4 and TSH are the critical
thyroidal parameters that endocrinologists are
focused on as measurable thyroidal end points
of concern, although there remains uncertainty
over which of these is most important.
Thus, to cause an adverse neurodevelop-
mental effect in the fetus, perchlorate would
have to be present at levels sufﬁcient to cause
hypothyroidism and thus cause a measurable
decrease in maternal T4 or increase in mater-
nal TSH. In the present report, we calculated
BMD using FT4 and TSH measurements in
conjunction with calculated or measured
perchlorate doses from these three studies.
These calculations are compared with the
0.4 mg/kg-day NOAEL estimate from
the NAS.
Materials and Methods
Human Studies
Study of ingestion of perchlorate by volunteers.
Greer et al. (2002) gave perchlorate in drink-
ing water to 37 male and female volunteers for
14 consecutive days. This study is likely too
short in duration to find significant changes
in FT4 and TSH, based on the NAS (NAS
2005) statement that “iodide uptake would
most likely have to be reduced by at least 75%
for months or longer.” Nevertheless, it may be
useful to calculate a BMDL for short-term
exposure.
In the main study, four subjects of each
sex received a perchlorate dose of 0.02, 0.1, or
0.5 mg/kg-day. Subsequently, six women and
one man received a dose of 0.007 mg/kg-day
and one additional subject of each sex received
a dose of 0.02, 0.1, or 0.5 mg/kg-day (the
uptake study). All participants were instructed
to drink one-fourth of a mixture containing a
body-weight-adjusted daily dose at 0800,
1200, 1600, and 2000 hr on each scheduled
perchlorate ingestion day and to record the
time and volume of each ingestion.
Greer et al. (2002) collected blood samples
during the main study at the screening visit
held 6 days before the beginning of exposure,
on the day before the beginning of exposure
(0800 hr), exposure day 1 (1200 and 1600 hr),
exposure day 2 (0800, 1200, and 1700 hr),
exposure day 3 (0800 hr), exposure day 4
(0800 and 1200 hr), exposure day 8 (0800 hr),
exposure day 14 (0800, 1200, and 1700 hr),
postexposure day 1 (0900, 1200, and 1700 hr),
postexposure day 2 (0800 and 1700 hr), post-
exposure day 3 (0800 and 1700 hr), postexpo-
sure day 4 (0800 hr), and postexposure day 14
(0800 hr). Serum perchlorate was measured in
most of these 23 sampling times, and critical
thyroid function measurements (FT4 and
TSH) were obtained at 16 of these times.
In the uptake study, serum perchlorate
was not measured, and thyroid function
measurements were made only from blood
samples collected at the screening visit and on
exposure day 14 (0800 hr). The precise time
of each sample collection was recorded in both
studies. Also, RAIU measurements and urine
samples were collected at various times in both
studies.
Greer et al. (2002) found iodine uptake
to be inhibited at the three highest doses
but found no association between dose and
indicators of thyroid function, other than a
slight reduction in TSH levels in morning
blood draws during perchlorate exposure within
the highest exposure group (0.5 mg/kg-day),
with recovery during 15 days of postexposure.
This downward trend is opposite the effect
expected if it were due to perchlorate, although
TSH can be decreased in regions with iodine
deﬁciency.
Study of ammonium perchlorate workers:
I. Lamm et al. (1999) conducted a cross-sec-
tional study of workers engaged in the produc-
tion of either ammonium perchlorate (n = 37)
or sodium azide (control workers, n = 21) in
the same industrial complex. The workers
worked 12-hr shifts on 3 consecutive days fol-
lowed by 3 consecutive days off. They rotated
shifts from days to nights monthly. Forty per-
cent of the perchlorate production workers
and 50% of the control workers had been
employed for > 5 years.
Lamm et al. (1999) measured urinary per-
chlorate in each worker at the beginning and
at the end of one shift. Postshift blood sam-
ples were obtained from all but one worker.
The critical thyroid parameters measured
were serum FTI and TSH. A perchlorate
elimination half-life of 8 hr was estimated by
monitoring urinary perchlorate in two of the
more highly exposed workers for 3 sub-
sequent days in which there was no known
perchlorate exposure. The absorbed perchlo-
rate dose (milligrams per shift) of each worker
was then estimated by applying a first-order
elimination model to the pre- and postshift
measurements of perchlorate per gram of cre-
atinine, assuming a creatinine excretion rate
of 1 mg/min and a perchlorate elimination
half-life of 8 hr.
Workers were grouped into four exposure
categories with mean absorbed perchlorate
dosages of 1, 4, 11, and 34 mg of perchlorate
per day. No differences in thyroid function
parameters were found between these groups.
Study of ammonium perchlorate workers:
II. Braverman et al. (2005) conducted a cross-
sectional study of 29 workers employed in the
same ammonium perchlorate production
facility that was studied earlier by Lamm et al.
(1999). Twelve community controls were also
studied. The minimum duration of employ-
ment in ammonium perchlorate manufacture
among the workers was 1.7 years, and the
median was 5.9 years. This study was con-
ducted approximately 6 years after the earlier
study, and several workers were included in
both study cohorts.
The workers worked the same shift pattern
(12 hr on, 12 hr off for 3 consecutive days,
followed by 3 days off) as in the Lamm et al.
(1999) study. The study period for each
worker encompassed work shifts on 3 con-
secutive nights, Tuesday through Thursday.
Among the employees with the highest
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75% or more after 3 consecutive 12-hr shifts.
Urine and blood samples were collected
from workers on Tuesday morning before
their ﬁrst night shift and at the beginning and
end of the Thursday night shift. Community
controls had their blood and urine sampled
once, on Tuesday morning. Tuesday and
Friday morning serum samples were analyzed
for TSH, FTI, and perchlorate. Thursday
evening serum samples were analyzed for per-
chlorate only. Creatinine and perchlorate were
measured in all urine samples.
Serum FTI was slightly but significantly
increased in the workers on Friday morning
compared with Tuesday morning, and TSH
was lower on Tuesday morning in perchlorate
workers than in community controls. Both
of these responses are opposite what would be
expected from perchlorate exposure. Otherwise,
there were no statistically significant differ-
ences in FTI or TSH in perchlorate workers
between results on Tuesday and Friday morn-
ings, or between perchlorate workers and
community controls on Tuesday morning.
Methods
Determination of serum half-life and volume
of distribution. To estimate perchlorate expo-
sures in the Braverman et al. (2005) occupa-
tional study, we need estimates of the half-life,
t1/2, and volume of distribution, Vd, of per-
chlorate. These parameters were estimated
using the Greer et al. (2002) study of perchlo-
rate uptake in volunteers.
The elimination of perchlorate from serum
was assumed to be a first-order process with
time constant β = ln(2)/t1/2. The movement of
perchlorate from the gut into the systemic cir-
culation was described by active transport with
time constant α. If at time t0 an amount D
(milligram per kilogram body weight) of
perchlorate is ingested, the resulting serum
concentration of perchlorate at time t, C(t)
(milligram per liter), satisfies the differential
equation
dC/dt = [rate in from gut] – [rate into urine]
= [(αD/Vd) exp(–α[t – t0])] – (βC). [1]
Solving, the contribution to serum by per-
chlorate ingested at time t0 is
C(t) = [α/(α – β)] (D/Vd) (exp[–β(t – t0)] 
– exp[– α(t – t0)]). [2]
By summing the contributions from each
ingestion time, t0, the total predicted serum
concentration at each serum sample time, t, in
the Greer et al. (2002) study was calculated.
To estimate α, β, and Vd, the model
defined by Equation 2 was fit to the Greer
et al. (2002) serum perchlorate data assuming
that the serum measurements (either the
serum perchlorate concentrations or their log-
transforms) can be modeled as Ei,j + τi + εij,
where Ei,j is the measurement predicted by
the above model (or its log-transform) for the
ith subject at the jth measurement time, and
τi and εij (where i and j index subject and
measurement time, respectively) are inde-
pendent and normally distributed with zero
mean, τi having standard deviation, στ, that
represents interindividual variability, and εij
having standard deviation, σε, that represents
measurement error and temporal variability.
It follows that the variance of a serum meas-
urement is στ
2 + σε
2, and the correlation
between two measurements is στ
2/(στ
2 + σε
2)
if the measurements are from the same indi-
vidual, and zero otherwise.
Estimation of absorbed doses in Braverman
et al. We used the values for serum half-life,
t1/2, and volume of distribution, Vd, estimated
from the Greer et al. (2002) study to estimate
the perchlorate exposure for each worker in the
Braverman et al. (2005) occupational study.
We obtained two sets of estimates, one based
on serum concentrations and one based on
urine concentrations. Retaining the assump-
tion that the elimination of perchlorate from
serum is a first-order process, and assuming
that inhaled perchlorate taken up by the lungs
immediately enters the systemic circulation,
the concentration (mg/L) in serum at the end
of a 12-hr shift is
C0 × exp(–12 × β) + [r/(Vd × w × β)] 
× [1 – exp(–12 × β)], [3]
where C0 is the serum concentration (mg/L)
at the beginning of the shift, r is the uptake
rate of perchlorate (milligrams per hour,
assumed constant throughout a shift for a
given worker), and w is body weight (kilo-
grams). Summing terms of this form for each
of the first two shifts yielded an expression
for the predicted concentration at the begin-
ning of the third shift that was set equal to a
worker’s measured serum concentration and
solved for the uptake rate, r, for the ﬁrst two
shifts. Using this value of r, the concentration
predicted at the beginning of the third shift
was used as C0 in Equation 3, and the result-
ing predicted concentration at the end of the
third shift was set equal to the measured serum
level to determine a worker’s uptake rate, r,
associated with the third shift.
We applied a conceptually similar approach
to the perchlorate urinary concentrations (mil-
ligrams per gram creatinine) measured at the
beginning and end of the third shift to estimate
the uptake rate for the third shift based on the
urine data. This analysis assumed the serum
half-life, t1/2, estimated from the Greer et al.
(2002) study and a constant creatinine elimi-
nation rate of 1 mg/min for all workers. This
approach requires knowledge of the time
since the most recent bladder void, which was
not recorded. Different values of this time
ranging from zero to 12 hr were considered.
Data used for benchmark calculations.
BMD calculations for the Lamm et al. (1999)
study used postshift serum TSH and FTI
measurements from both control and perchlo-
rate workers. Calculations for the Braverman
et al. (2005) study used TSH and FTI meas-
urements collected from perchlorate workers
and community controls on Tuesday morn-
ing, just before the Tuesday–Thursday night
shifts. In both cases, the dose used in the cal-
culation was a worker’s estimated average daily
dose (milligrams), calculated as one-half of his
estimated shift dose (reﬂecting the 3-day-on/
3-day-off pattern of work).
BMD calculations for the Greer et al.
(2002) study used TSH and FT4 data obtained
from serum collected at the screening visit, on
the day before the beginning of exposure, and
on the last day of exposure (exposure day 14).
To reﬂect to the fullest any effect of perchlo-
rate exposure, measurements from serum col-
lected after exposure began but before the last
day of exposure were not used. The perchlorate
dose (milligrams) assumed for serum collected
on exposure day 14 was the assigned daily dose
(0.007, 0.02, 0.1, or 0.5 mg/kg), multiplied by
a subject’s body weight.
Statistical analysis. In modeling the
FTI and TSH data from Lamm et al. and
Braverman et al. cohorts, it was assumed that
a thyroid measurement, or its log-transform,
was normally distributed with mean
α + β × doseK [4]
and constant SD, σ, where dose is the daily
perchlorate dose in milligrams.
When applied to the Greer et al. (2002)
FT4 and TSH data, we expanded the model
deﬁned by Equation 4 in two ways. First, an
error structure was assumed like that applied
to the Greer et al. (2002) serum perchlorate
data (described above) that accounted for
repeated measurements made in the same
individual. Second, to account for potential
daily variation in FT4 and TSH, the parame-
ter α was allowed to assume different values
depending on the time of day a sample was
collected (before 1000 hr, between 1000 hr
and 1400 hr, and after 1400 hr).
Unless otherwise specified, we estimated
model parameters using maximum likelihood,
hypothesis tests were likelihood ratio tests,
and we computed 90% confidence intervals
(90% CIs) by the profile likelihood method
(Cox and Hinkley 1974; Crump 2002b;
Venzon and Moolgavkar 1988). Residuals
from model ﬁts to the untransformed serum
measurements were tested by the Shapiro-
Wilk test for conformity with a normal distri-
bution (Shapiro and Wilk 1965). If normality
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repeated using the log-transform of the serum
measurements. If the data were still non-
normal, any outliers present were omitted (an
outlier deﬁned as a measurement whose resid-
ual was more than three times the SE) and the
data retested for normality. The reported
analysis was the one in which the residuals
conformed most closely to normality. Because
the potential adverse effect of perchlorate is
an increase in TSH or a decrease in T4, the
maximum likelihood estimate of β was not
allowed to be negative when calculating
BMDLs for TSH and not allowed to be
positive when calculating BMDLs for FTI
or FT4. To avoid biologically implausible
dose–response curve shapes, the shape parame-
ter, K, was not allowed to be < 1.0 (Crump
2002a) and, for computational reasons, was
not allowed to exceed 10. Because there was
no significant effect of dose on any thyroid
parameter, K was allowed to differ from 1.0
only in BMD calculations. All calculations
were performed in Excel (version 2002 SP3;
Microsoft Corporation, Redmond, WA).
Excel Visual Basic macros were used to calcu-
late likelihoods, and parameters were esti-
mated by maximizing the likelihood using the
Excel optimizer routine.
Benchmark analysis. A BMD is a dose cor-
responding to a speciﬁed change in response.
For binary data coded as presence or absence of
disease, the response is usually deﬁned as the
probability of disease. For continuous data,
such as serum thyroid measurements, there is
less agreement regarding how the BMD should
be deﬁned.
In the present analysis, the BMD is deﬁned
as the change in the mean serum measurement
equal to a factor, Q, times the SD of the meas-
urements. It follows from this deﬁnition and
Equation 4 that BMD = (Q × σ/β)1/K. BMD
calculations are presented using three different
values for Q: 1.0, 0.82, and 0.52. In its bench-
mark technical guidance document, the U.S.
EPA recommends that this method with Q = 1
(termed the “SD approach”) always be among
the methods applied (U.S. EPA 2000a). The
other two values, Q = 0.82 and Q = 0.52, are
derived from the equivalent “hybrid” approach
for deﬁning a BMD, as explained below.
In the “hybrid” approach for defining a
BMD from a continuous response, the pro-
portion P(0) of unexposed individuals whose
response is considered adverse is ﬁrst speciﬁed,
and the BMD is defined as the dose that
increases the probability of an adverse response
by a speciﬁed amount termed the benchmark
risk (BMR) (Budtz-Jørgensen et al. 2001;
Crump 1995; Crump et al. 2000; Gaylor and
Slikker 1990; Kodell et al. 1995; West and
Kodell 1993). This approach is conceptually
similar to that generally applied to binary
responses, and consequently its use provides
comparability between BMR calculated from
continuous and binary data. It can be shown
that the hybrid approach, when implemented
using Equation 4, is equivalent to the method
described above in terms of Q, with
Q =N–1[1 –P(0)] –N–1[1 –P(0) – BMR], [5]
where N–1 is the inverse of the standard nor-
mal distribution (Budtz-Jørgensen et al. 2001;
Crump 2002a).
The convention in evaluating serum thy-
roid clinical measurements is that the normal
range includes the measurements of 95% of a
normal (unexposed) population, and that
abnormal values include 2.5% of the lowest
measurements and 2.5% of the highest
measurements. Because an adverse effect of
perchlorate would be expected to result in
decreased FTI or FT4 and increased TSH,
P(0) was set to 0.025. Two values of BMR
were used with the hybrid method: 0.05 and
0.1. BMR = 0.1 has often been used by the
U.S. EPA when calculating a BMD from
binary data, and BMR = 0.05 represents a
more conservative choice. From Equation 5,
when combined with the choice P(0) = 0.025,
BMR = 0.1 is equivalent to Q = 0.82 and
BMR = 0.05 is equivalent to Q = 0.52.
Ideally, the BMD calculation should reﬂect
interindividual variation but not measurement
error. In most data sets, it is not possible to
separate contributions to variation from these
two sources. However, in the Greer et al.
(2002) study it is possible to separately esti-
mate interindividual variation because repeated
measurements were collected from each indi-
vidual. Consequently, in benchmark calcu-
lations based on the Greer et al. data, the
standard deviation for interindividual variabil-
ity, στ, was used in place of the total standard
deviation, σ = (στ
2 + σε
2)1/2.
Each of the data sets from which BMD
calculations were made was negative; that is,
there was no statistically signiﬁcant evidence
of a relationship between perchlorate dose
and thyroid function. Even if there is appar-
ently no effect of dose, a BMDL calculated
from such negative data still represents a valid
lower bound on the dose corresponding to
any (undetected) effect of perchlorate that
may have been present. There are a number
of examples in the literature where a BMD
analysis has been applied to data in which no
adverse effects were detected (Clewell et al.
2000, 2003; Crump et al. 2000; NAS 2000).
Because the Lamm et al. (1999) and
Braverman et al. (2005) studies were con-
ducted in the same facility and made compa-
rable measurements of thyroid function and
perchlorate dose, we conducted a combined
benchmark analysis of these two data sets. In
this analysis the basic model (Equation 4) was
expanded to account for potential differences
between the two studies in laboratory tech-
niques for measuring FTI and TSH, and for
potential drift in normal thyroid function val-
ues. In the expanded model, the responses in
one study were assumed to differ from the
other, on average, by a ﬁxed factor. This was
accomplished by retaining Equation 4 to
model the Lamm et al. data, but in modeling
the Braverman et al. data multiplying both
the mean (Equation 4) and the standard devi-
ation, σ, by the same free parameter. The
BMD as deﬁned herein is functionally inde-
pendent of this parameter.
The BMDL was calculated as a 95% statis-
tical lower bound on the BMD in all instances.
Results
Serum half-life and volume of distribution. In
ﬁtting the perchlorate uptake and elimination
model (Equation 1) to the Greer et al. (2002)
serum perchlorate data, we included only data
from subjects in the main study exposed to the
two highest doses (0.5 and 0.1 mg/kg/day).
Serum perchlorate was not measured in the
uptake study, and perchlorate was below the
level of detection in most (58 of 62) of the
serum measurements in subjects exposed to
0.02 mg/kg-day. Ninety-one additional sam-
ples in which no perchlorate was detected
were also omitted. All but three of these were
collected after dosing had ceased. One of these
three appears to be an error, and the remain-
ing two were collected from a single individual
in the 0.1 mg/kg-day exposure group during
the first day of exposure. After these exclu-
sions, there remained 238 serum perchlorate
measurements from the Greer et al. study
available for analysis.
The log-transformed serum concentrations
were described much better by a normal distrib-
ution than by the untransformed concentra-
tions. After elimination of four outliers, the
residuals from ﬁtting the log-transform of the
model (Equation 1) to the log-transforms of the
concentrations were marginally well described
by a normal distribution (p = 0.04). Figure 1
shows, as an example, the serum concentration
data for a subject in the 0.5 mg/kg-day dose
group compared with the concentration proﬁle
predicted by the best-ﬁtting model. The con-
centration spikes resulting from each of the
four ingested doses on each of the 14 dosing
days are visible in this graph. The peak serum
concentration is predicted to have occurred at
about 2200 hr each evening, a couple of hours
after the last scheduled ingested dose for the
day, and several hours after any scheduled
serum measurement.
Based on this analysis, the half-life of per-
chlorate in serum was estimated as t1/2 = 7.5 hr
(90% CI, 7.2–7.8) and the volume of distribu-
tion as Vd = 0.34 L/kg (90% CI, 0.31–0.39).
The estimated between-subject and within-
subject SD were στ = 0.24 and σε = 0.25.
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(by at most 8%) when outliers were not
removed or when a normal distribution was
assumed.
Using the best estimates from Greer et al.
(2002) for the elimination half-life (t1/2 =
7.5 hr) and volume of distribution (Vd =
0.34 L/kg) for perchlorate, and Equation 3, we
estimated the average per-shift dose (milligrams
per shift) of each worker in the Braverman et al.
(2005) study from the serum perchlorate meas-
urements. Separate estimates were obtained for
the ﬁrst two shifts combined and for the third
shift, and a weighted average of these two esti-
mates was used as the average dose per shift for
a worker.
Figure 2 compares the estimated per-shift
dose for the ﬁrst two shifts with the estimated
dose for the third shift. Although there is a wide
range in individual doses, from 0.41 mg/shift to
392 mg/shift, the difference in individual shift
doses between the ﬁrst two shifts and the third
shift are relatively small in most cases, which
supports the assertion that workers tended to
work in similar jobs on different shifts.
Figure 3 compares estimates of dose dur-
ing the third shift computed using urine data
with those computed using serum data. The
estimates based on the urine data assumed
that the data are from a 4-hr void. By com-
parison, if a theoretical “instantaneous” void
was assumed, these estimates were about 10%
smaller, and if a 12-hr void was assumed, they
were about 50% larger. Because the dose esti-
mates based on the urine data were only for
the third shift, and because of the uncertainty
in both the void time for the urine samples
and the rate of creatinine elimination, the
average dose per shift over the three shifts
obtained from the serum data were used in
the benchmark analysis.
Benchmark results. In the Lamm et al.
(1999) study, the residuals of the FTI were
adequately described by a normal distribution
(p = 0.38), and after eliminating one TSH
measurement that was four times larger than
that of any other worker, the residuals from
the log-transformed TSH measurements were
also normal (p = 0.12). In Braverman et al.
(2005), both the residuals of the FTI measure-
ments and the log-transformed TSH measure-
ments were adequately described by a normal
distribution (p = 0.54 and 0.16, respectively).
Consequently, BMD analyses of FTI from
these studies used the untransformed measure-
ments, whereas analyses of TSH used the log-
transformed measurements.
The model fit to the combined Lamm
et al. (1999) and Braverman et al. (2005) data
sets contained four estimated parameters,
compared with the total of six that were esti-
mated from the separate fits to the two data
sets. By adding the log-likelihoods from the
individual ﬁts, we determined that the com-
bined individual fits were not significantly
better than the ﬁt of the single model to the
combined data (p = 0.52 and 0.98, 2 df, for
FTI and TSH, respectively). The multiplica-
tive factors needed to adjust the Braverman
et al. results to conform to the Lamm et al.
results were 0.38 for FTI values and 0.85 for
the logarithms of TSH.
The estimated average daily exposure of one
worker from the Braverman et al. cohort was
84 mg/day, which was more than twice that of
any other worker. Although this worker’s FTI
and TSH values were not exceptional, the
BMDLs were highly dependent on this single
data point. Consequently, BMDLs were calcu-
lated both with this inﬂuential point included
and with it omitted.
Figure 4 shows plots of the FTI measure-
ments from Lamm et al. along with the
adjusted FTI measurements from Braverman
et al. Figure 5 shows comparable plots for the
logarithm of TSH. These figures also show
the maximum likelihood model fits that
define the BMD (termed “BMD curve” in
the ﬁgures) and the model curves that deﬁne
the BMDL for the case Q = 1, both using all
data and with the influential point omitted.
The calculation of the BMDLs for Q = 1 are
illustrated graphically.
Table 1 contains the BMD and BMDL
estimates obtained from the combined data
from the two occupational studies using all
three values of Q, both including and omit-
ting the influential data point. Also shown
are the values of the shape parameter, K,
corresponding to each BMDL calculation.
The BMD estimates for TSH were infinite,
because in both cases the maximum likeli-
hood estimate of the parameter β was zero.
Nevertheless, the corresponding BMDLs were
all ﬁnite. The six calculations of BMDL based
on all the data ranged from 24 to 83 mg/day
or, by dividing by the average body weight in
the study of 90 kg, from 0.27 to 0.92 mg/kg-
day, and those with the inﬂuential point elim-
inated ranged from 16 to 39 mg/day, or from
0.18 to 0.43 mg/kg-day.
Turning now to the Greer et al. (2002)
study, after elimination of two outliers, residuals
Benchmark calculations for perchlorate
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Figure 1. Serum perchlorate measurements for a subject from Greer et al. (2002) dosed at 0.5 mg/kg/day,
versus expected concentrations.
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Figure 2. Comparison of shift doses in Braverman
et al. (2005): average dose in first two shifts com-
pared with third-shift dose.
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Figure 3. Comparison of shift doses in Braverman
et al. (2005): third-shift doses estimated from urine
or serum data.
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remaining 134 FT4 measurements from this
study were adequately described by a normal
distribution (p = 0.11). Likewise, after elimi-
nation of two outliers, residuals from fitting
the model to the log-transforms of the
remaining 137 TSH measurements were nor-
mally distributed (p = 0.49). Time of day was
a signiﬁcant predictor of TSH (p = 0.0002),
but not of FT4 (p = 0.24), with TSH meas-
urements made before 1000 hr being larger
than those made later in the day, but with no
difference between midday and afternoon
measurements. Consequently BMD analyses
for FT4 did not allow for differences in time
of day, whereas those for TSH permitted
morning measurements to be different from
those made later in the day. TSH was signiﬁ-
cantly decreased in serum collected at the
conclusion of the 14-day exposure period (p =
0.002), whereas the expected effect of per-
chlorate would be to increase TSH.
Table 2 summarizes the benchmark calcu-
lations made from the Greer et al. (2002)
short-term study. The BMD analyses for TSH
assumed that an increase in TSH was adverse,
despite the fact that a signiﬁcant decrease was
observed. The BMDLs from this study are all
in a relatively narrow range, between 49 and
60 mg/day or, after dividing by the average
body weight in the study of 76.4 kg, between
0.64 and 0.79 mg/kg-day, which is within the
range of the BMDLs obtained from the occu-
pational studies (Table 1).
Discussion
The Lamm et al. (1999) and Braverman et al.
(2005) studies were conducted 6 years apart in
the same plant on overlapping cohorts. The
same types of serum measurements were col-
lected in the two studies. A single model that
accounted for potential differences in serum
thyroid measurement techniques, and for
potential drift in normal thyroid function val-
ues, ﬁt the combined data statistically as well
as the separate models ﬁt the individual data
sets. The BMDLs from this combined analysis
ranged from 0.18 to 0.56 mg/kg-day for FTI
and from 0.36 to 0.92 mg/kg-day for TSH.
The BMDLs from the Greer et al. (2002)
study were within the range of those from the
two occupational studies.
None of the three studies found evidence
of an effect of perchlorate on thyroid func-
tion. Nevertheless, BMDLs calculated from
such negative results represent valid statistical
lower bounds on the dose that accounts for a
potential, but unobserved, effect of perchlo-
rate. However, BMDLs such as these based
on negative data could possibly be highly con-
servative (Clewell et al. 2000; Crump et al.
2000).
Forty percent of the perchlorate workers in
the Lamm et al. cohort had worked at the facil-
ity for > 5 years, and 50% of the workers in the
Braverman et al. cohort had worked for at least
5.9 years. Based on jobs assigned to workers
during the previous year and estimated perchlo-
rate exposures in each job, Braverman et al.
(2005) estimated a median shift dose over the
previous year of 0.33 mg/kg. Therefore, the
BMDLs obtained from the combined analysis
of the two occupational studies pertain to expo-
sures extending to 5 years or more in duration.
Overall, the BMDLs calculated from the occu-
pational studies are in excellent agreement with
the NOAEL of 0.4 mg/kg-day obtained by the
NAS based on clinical studies (NAS 2005).
In addition to BMDLs from the com-
bined occupational cohorts, BMDLs were
also computed from the two studies individu-
ally (results not shown). As expected, BMDLs
from the combined data were larger than the
smallest BMDLs from the individual data sets
and tended to be either intermediate between
those calculated from the individual data sets,
or somewhat larger than the larger of the two
BMDLs obtained from the individual data
sets. Given that the two occupational studies
had similar designs, that they were conducted
in the same facility, and that the data were
compatible with a single model, we believe
the combined analysis makes the most appro-
priate use of the data from these studies.
The BMD calculations for the Braverman
et al. (2005) cohort were based on serum
Crump and Gibbs
1006 VOLUME 113 | NUMBER 8 | August 2005 • Environmental Health Perspectives
Figure 4. FTI data from Lamm et al. (1999) and scaled FTI data from Braverman et al. (2005) versus estimated
daily perchlorate dose, with graphical indication of the BMDL calculation for Q = 1 (BMD deﬁned as change
in mean response equal to SD).
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Figure 5. Log-transformed TSH data from Lamm et al. (1999) and scaled FTI data from Braverman et al. (2005)
versus estimated daily perchlorate dose, with graphical indication of the BMDL calculation for Q = 1 (BMD
deﬁned as change in mean response equal to SD).
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σobtained from perchlorate workers on Tuesday
morning when they had been without per-
chlorate exposure for > 2 days. It could be
hypothesized that this lack of recent exposure
had allowed recovery time that obscured some
perchlorate effect. To evaluate this possibility,
BMDLs for Q = 1 based on the complete data
set were recalculated after replacing the work-
ers’ Tuesday morning serum values with their
Friday morning values. In both cases, the esti-
mated effect was opposite that expected from
exposure to perchlorate, and the two BMDLs
were within 4% (FTI) and 50% larger (TSH)
than the corresponding BMDLs based on the
Tuesday morning data (Table 1). Thus, there
was no indication in the data that lack of
very recent exposure had allowed time for
recovery.
The perchlorate doses used for the Lamm
et al. study (1999) were those estimated in the
original study, which used a perchlorate half-
life of 8 hr compared with the 7.5 hr used for
the Braverman et al. study, based on the Greer
et al. study. This difference is expected to make
no more than a 7% difference in the computed
doses. Also, the formula used by Lamm et al.
to calculate the shift doses effectively assumed
an instantaneous void. More realistic assump-
tions would result in slightly larger estimated
doses and corresponding larger BMD esti-
mates. For example, if a 4-hr void is assumed,
it is estimated that the doses would increase by
approximately 10%.
Merrill et al. (2003, 2004) used data from
the Greer et al. (2002) study in developing a
physiologically based pharmacokinetic model
for the kinetics and distribution of both iodine
and perchlorate, and for the inhibition of
thyroid uptake of radiolabeled iodide by per-
chlorate. Although the two figures are not
entirely comparable, the time course of serum
perchlorate in the Greer et al. study as pre-
dicted by the Merrill et al. model (Merrill et al.
2004; their Figure 6) appears to be very similar
to that shown in Figure 1.
There have been three other BMD analyses
for perchlorate based on human data, all of
which used the Greer et al. (2002) study of
perchlorate consumption by volunteers. Two
of these analyses, performed by the California
Environmental Protection Agency’s Ofﬁce of
Environmental Health Hazard Assessment
(CAL/OEHHA 2004) and by the U.S. EPA
(2003), modeled the ratio of the RAIU
after perchlorate exposure to the baseline
RAIU value, and defined the BMD as the
dose corresponding to a 5% change in this
ratio. The OEHHA calculated a BMDL of
0.0037 mg/kg-day, which in a 70-kg individ-
ual is equivalent to 0.26 mg/day. The U.S.
EPA calculated a large number of BMDLs but
emphasized some that correspond to a range of
about 0.09–0.7 mg/day. These values are
much smaller than the BMDLs obtained in the
present analysis either from the Greer et al.
study (Table 2) or from the occupational stud-
ies (Table 1). The main reason for this dif-
ference is that an RfD has traditionally been
based on an adverse response, and the present
analysis did not consider reduction in uptake
of labeled iodine, without accompanying
changes in critical thyroid parameters, to be
adverse.
A third BMD analysis based on the Greer
et al. study (2002) was conducted for the
National Aeronautics and Space Adminis-
tration by ICF Consulting (2004). BMDLs
were calculated from data on FT4, T4, and
T3. The thyroidal measurements for an indi-
vidual at each of three measurement times
(morning, midday, and afternoon) on day 14
minus the average of his or her measurements
on two preexposure days and one postexpo-
sure day was modeled. For each of these nine
cases, BMDLs were calculated corresponding
to 5, 10, or 20% change in response. This
resulted in 27 BMDLs that, after multiplying
the average body weight in this study of
76.4 kg, range from 7 to 89 mg/day. The
nine BMDLs calculated for FT4 correspond
to a range of 8–76 mg/day, which contains
the range of BMDLs for FT4 obtained in the
present analysis both from the Greer et al.
study (Table 2) and from the occupational
studies (Table 1). The differences between the
ICF results and those from the present analy-
sis for FT4 are likely due largely to the deci-
sions by ICF to segment the data by time of
day (vs. our approach of using all the data and
controlling for time of day) and to exclude
the data from the uptake study. As a result,
the BMDLs obtained by ICF (2004) were
based on at most 22 serum values collected
during exposure, whereas BMDLs for FT4
obtained in the present analysis (Table 2)
were based on 75 such values. The ICF analy-
sis also employed a different deﬁnition of the
BMD than was used in the present analysis
and employed a linear model as opposed to
the nonlinear model used in the present
analysis.
A more flexible dose–response model
(e.g., a nonlinear model that contains a linear
model as a particular case) will always result
in a BMDL at least as small as that resulting
from a less ﬂexible model (e.g., a linear one).
Consequently, the nonlinear model employed
herein, with shape parameter K = 1, will never
result in a larger BMDL than will use of a lin-
ear model (K = 1). Allowing the dose response
to be highly nonlinear can also prevent the
BMDL from appreciably exceeding the doses
in a negative study. For example, the BMDLs
calculated herein from the Greer et al. study
range from 49 to 60 mg/day, whereas the
largest exposure in this study was 50 mg/day.
Notice also that, for the occupational studies,
the values of the shape parameter, K, esti-
mated in conjunction with the BMDL
(Table 1) increase with increasing BMDL or,
equivalently, as the BMDLs get closer to the
highest dose in the study.
Benchmark calculations for perchlorate
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Table 1. BMD estimates (mg/day) and corresponding BMDLs for perchlorate obtained from two occupational
studies (Braverman et al. 2005; Lamm et al. 1999).
Thyroid indicator P(0) BMR Q BMD BMDL BMDL Ka
All data
FTI 0.025 0.05 0.52 67 24 1.0
0.025 0.1 0.81 98 38 1.0
0.025 1 118 50 1.2
TSH 0.025 0.05 0.52 INF 57 1.3
0.025 0.1 0.81 INF 76 2.1
1 INF 83 6.0
Eliminating inﬂuential point
FTI 0.025 0.05 0.52 34 19 1.1
0.025 0.1 0.81 42 27 1.5
1 47 30 1.8
TSH 0.025 0.05 0.52 INF 32 1.9
0.025 0.1 0.81 INF 38 4.5
1 INF 39 6.9
Abbreviations: INF, inﬁnite; Q, factor.
aValue of shape parameter, K, estimated in BMDL calculation.
Table 2. BMD estimates (mg/day) and corresponding BMDLs for perchlorate obtained from the Greer et al.
(2002) study of perchlorate ingestion by volunteers.
Thyroid indicator P(0) BMR Q BMD BMDL BMDL Ka
FT4 0.025 0.05 0.52 INF 49 10
0.025 0.1 0.81 INF 52 10
1 INF 53 10
TSH 0.025 0.05 0.52 INF 56 10
0.025 0.1 0.81 INF 59 10
1 INF 60 10
Q, factor.
aValue of shape parameter, K, estimated in BMDL calculation.REFERENCES
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